Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
How can fatigue be recognized and managed?
The importance of non-pharmacological interventions in myeloproliferative neoplasms
Managing challenging patients with Waldenstrom macroglobulinemia
What are the biggest challenges associated with treating MGUS?
Niels van de Donk